AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
73.03
-1.06 (-1.43%)
Mar 25, 2025, 4:00 PM EST - Market closed
AstraZeneca Revenue
In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth. AstraZeneca had revenue of $14.89B in the quarter ending December 31, 2024, with 23.84% growth.
Revenue (ttm)
$54.07B
Revenue Growth
+18.03%
P/S Ratio
4.20
Revenue / Employee
$582,056
Employees
92,900
Market Cap
227.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
| Abbott Laboratories | 41.95B |
AZN News
- 4 days ago - AstraZeneca to Invest $2.5 Billion in China Amid Probes - WSJ
- 4 days ago - Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies - PRNewsWire
- 4 days ago - British pharma giant AstraZeneca to invest $2.5 billion in new China hub - CNBC
- 4 days ago - AstraZeneca investing $2.5 bln in China as drugmaker seeks to recover from scandals - Reuters
- 6 days ago - Mindpeak to deploy and evaluate AI-Powered Digital Pathology Risk Assessment Tools for Breast Cancer in collaboration with AstraZeneca - Business Wire
- 8 days ago - IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals - PRNewsWire
- 8 days ago - AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy' - The Guardian
- 8 days ago - AstraZeneca Buys EsoBiotec for Up to $1 Billion - WSJ